Article By:
Modest Money
Tuesday, April 2, 2019 6:54 PM EDT
The stock has returned 56% year-to-date. It is currently trading at price to sales ratio of 574.17 and P/B ratio of 41.92.
In this article: CRMD
Is CorMedix Overvalued?
I think this article is rather pointless as it doesn't really share anything new. Why is $CRMD overvalued? Do you have reason to think #Neutrolin won't be approved?